Abstract
The field of immuno-oncology (IO) is rapidly expanding, generating enormous interest on the part of drug developers and giving new hope to patients and physicians. Attempts to harness the immune system to fight cancer date back to the 19th century; however, it is only in recent years that immunotherapies have entered mainstream oncology and have shown promise across a broad range of tumor types. New therapeutic combinations are emerging, with companies pairing two immunotherapies, an immunotherapy and a molecularly targeted therapy, or an immunotherapy plus traditional chemotherapy in order to more effectively fight cancer. Some immunotherapies are also pairing with companion diagnostics in order to maximize efficacy in patient populations. All of these developments come with their own unique challenges that drug developers will need to confront. This Perspective article reviews developments in the IO field and highlights key challenges in successfully commercializing an IO therapy.
Keywords: Commercialization, companion diagnostics, immuno-oncology, oncology, precision medicine.
Current Pharmacogenomics and Personalized Medicine
Title:IO Nation: The Rise of Immuno-Oncology
Volume: 12 Issue: 3
Author(s): Scott Palmer, Georgiana L. Kuhlmann and Kristin Pothier
Affiliation:
Keywords: Commercialization, companion diagnostics, immuno-oncology, oncology, precision medicine.
Abstract: The field of immuno-oncology (IO) is rapidly expanding, generating enormous interest on the part of drug developers and giving new hope to patients and physicians. Attempts to harness the immune system to fight cancer date back to the 19th century; however, it is only in recent years that immunotherapies have entered mainstream oncology and have shown promise across a broad range of tumor types. New therapeutic combinations are emerging, with companies pairing two immunotherapies, an immunotherapy and a molecularly targeted therapy, or an immunotherapy plus traditional chemotherapy in order to more effectively fight cancer. Some immunotherapies are also pairing with companion diagnostics in order to maximize efficacy in patient populations. All of these developments come with their own unique challenges that drug developers will need to confront. This Perspective article reviews developments in the IO field and highlights key challenges in successfully commercializing an IO therapy.
Export Options
About this article
Cite this article as:
Palmer Scott, Kuhlmann L. Georgiana and Pothier Kristin, IO Nation: The Rise of Immuno-Oncology, Current Pharmacogenomics and Personalized Medicine 2014; 12 (3) . https://dx.doi.org/10.2174/1875692113666150115222451
DOI https://dx.doi.org/10.2174/1875692113666150115222451 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Immunotargets in Bladder Cancer
Current Drug Targets Absorption, Pharmacokinetics and Disposition of Biodegradable Nanoscale Preparations
Current Drug Metabolism ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Current Cancer Drug Targets Transient Receptor Potential (TRP) Channels and Cardiac Fibrosis
Current Topics in Medicinal Chemistry Polymer-Based Gene Delivery: A Current Review on the Uptake and Intracellular Trafficking of Polyplexes
Current Gene Therapy Emerging Role of Mucins in Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC
Current Pharmaceutical Design Radioimmunotherapy of Infection with 213Bi-Labeled Antibodies
Current Radiopharmaceuticals The Role of CXCR3 in Neurological Diseases
Current Neuropharmacology Influence of Oxidative Stress on Catalytic and Non-glycolytic Functions of Glyceraldehyde-3-phosphate Dehydrogenase
Current Medicinal Chemistry Meet Our Editorial Board Member
Endocrine, Metabolic & Immune Disorders - Drug Targets The Yin and Yang of Antiviral Innate Immunity in Central Nervous System
Current Pharmaceutical Design Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study
Current Vascular Pharmacology Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Characterization and Pharmacokinetic Evaluation of Gamma Sterilized Ketorolac Tromethamine Loaded Albumin Microspheres for Intramuscular Administration
Current Drug Delivery Rapid Estrogen Signaling in Spermatogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pancreatic Cancer in Obesity: Epidemiology, Clinical Observations, and Basic Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Molecular Modeling Investigation of Some New 2-mercaptoimidazoles
Current Computer-Aided Drug Design A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry